VIEW ONLINE

  • Innovation Capacity

    Innovation Capacity

    Referring to FDA and EU management system, we set up a R&D management platform to promote the introduction of innovative products, clinical research and registration. We have developed dozens of state-level new drugs, achieving a leading position in the ophthalmic and cardiovascular fields and actively expanding into the fields of amino acids and specialty API at the same time. Our focus areas include cardiovascular and cerebrovascular emergency treatment, interventional therapy, respiration, otolaryngology and ophthalmology, rare diseases and biological health. At present, we have more than 30 independent R&D products, and nearly 80 R&D products in the project with abundant R&D resources in the system.

  • Global Expansion

    Global Expansion

    Leveraging capital advantages, we have carried out in-depth joint venture cooperation with Cardionovum in German, Conavi in Canada, Sirtex in Australia, Oncosec in the United States and Glenmark in India and other companies with high-end cardiovascular medical devices and innovative drugs which have high technological values or professional reinforcement. We have successively introduced a group of the world's pioneer innovative drug products in the fields of liver cancer, high-end cardiovascular equipment, tumor immunotherapy products, parainfluenza virus innovative drugs, and sepsis treatment, as well as the construction of overseas research and development centers, etc., to continuously improve the international innovation layout.

  • R & D team

    R & D team

    We have a professional R&D team with more than 400 high-end development and technical personnel with master's degree or above. Drug development experts and professional experts with international and domestic background from the United States, Belgium, Canada, Australia and India and other countries have joined us as our long-term advisers to ensure that we can continuously achieve innovative breakthroughs and development.

  • Patented Technology

    Patented Technology

    Focusing on the layout of core patents for key products, we have carried out overseas patent applications and applied for 628 patents in recent years and obtained 354 patent authorizations. In 2016, we were selected as a National Intellectual Property Demonstration Enterprise. Up to 2019, four member companies have been awarded as "The National Intellectual Property Competitive enterprises"; one of the member companies has been awarded as "The National Intellectual Property Demonstration Enterprises"; nine member companies have been selected as provincial, municipal intellectual property demonstration enterprises.

  • 2020


    Became the National Enterprise Technology Center.


  • 2019


    Approved by the Ministry of Industry and Information Technology, as one of the second group of small variety (shortage medicine) centralized production base construction units;

    Ranked No.28 in the Chian’s Top 100 Chemical and Pharmaceutical Industrial Enterprises in terms of comprehensive strength;

    Became the Excellent Corporate Brand of China's Preparation Export-oriented in Pharmaceutical Industry, the Excellent Corporate Brand of API Export-oriented in Pharmaceutical Industry, also the Excellent Corporate Brand of Integration of Informatization and Industrialization in China's chemical and pharmaceutical industry;

    Eucalyptol, Limonene and Pinene Enteric Soft Capsules (trade name: Cherno) won The Excellent Product Brand of Other Medicines in China's Chemical and Pharmaceutical Industry;

    Ranked No. 36 in China’s Top 100 Pharmaceutical Industrial List;

    Grandpharma won The Fourth Annual Most Valuable Golden Hong Kong Stock Pharmaceutical and Medical Company and Best IR Hong Kong Company award.


  • 2018


    Ranked No. 54 in China's top 100 Pharmaceutical Industry List;

    Ranked No. 34 in China’s Top 100 Chemical and Pharmaceutical Industrial Enterprises in terms of comprehensive strength;

    Became the Excellent Corporate Brand of China's Preparation Export-oriented in Pharmaceutical Industry, the Excellent Corporate Brand of API Export-oriented in Pharmaceutical Industry, also the Excellent Corporate Brand of Integration of Informatization and Industrialization in China's Chemical and Pharmaceutical Industry;

    The "Producing Amino Acids by Fermentation and Enzymatic Conversion Technology" Project won the "Special Award for Green Pharmaceuticals in China's Chemical and Pharmaceutical Industry"; " Eucalyptus Lemon Pine Enteric Soft Capsule" (trade name: Cherno) won the " Excellent Drug Product Brand of Other Chemical and Pharmaceutical Industries " award;

    Grandpharma won 2018 The Most Valuable Pharmaceutical and Medical Stock Company of Golden Hong Kong Stock Award.


  • 2017


    Ranked No. 62 in China's Top 100 Pharmaceutical Industry List;位

    Ranked No. 38 in China’s Top 100 Chemical and Pharmaceutical Industrial Enterprises in terms of comprehensive strength;

    Became the Excellent Corporate Brand of China's Preparation Export-oriented in Pharmaceutical Industry;

    Became the Excellent Corporate Brand of Integration of Informatization and Industrialization in China's Chemical and Pharmaceutical Industry.


  • 2016


    Ranked No. 36 in China’s Top 100 Chemical and Pharmaceutical Industrial Enterprises in terms of comprehensive strength;

    Grandpharma was rewarded with Evaluation Certificate of Contemporary Management System for Integrated Informatization and Industrialization;

    One of the Top 10 Pharmaceutical Manufacturing Enterprise in Hubei Province.


  • 2015


    Ranked No. 38 in China's top 100 Chemical and Pharmaceutical Industry Enterprises in terms of comprehensive strength;

    Jointly built R&D platform for Rare Disease Drugs with Institute of Materia Medica Chinese Academy of Medical Science;

    Hubei Food and Drug Administration's Technical Evaluation and Verification Center awarded Grandpharma The Pharmaceutical GMP Training Base;

    Hubei Science and Technology Department approved as an Enterprise Technology Center.


  • 2013


    Xinweining (Tirofiban Hydrochloride) and Epinephrine Series won the award of Hubei Famous Brand Products;

    Set up a national post-doctoral research station to undertake more than 20 national, provincial and municipal science and technology projects, also received several provincial and municipal scientific and technological awards.


  • 2012


    The National Development and Reform Commission and the Ministry of Industry and Information Technology supported Grandpharma to be the "National Basic Medicine Production Base";

    Selected as one of the second group of innovative enterprises in Hubei Province.


  • 2005


    Became a National High Technology Expertise.


top